Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector

Journal of Infectious Diseases

Volumn 205, Issue 5, 2012, Pages 772-781

  O'Hara, Geraldine A ^a   Duncan, Christopher J A ^a   Ewer, Katie J ^a   Collins, Katharine A ^a   Elias, Sean C ^a   Halstead, Fenella D ^a   Goodman, Anna L ^a   Edwards, Nick J ^a   Reyes Sandoval, Arturo ^a   Bird, Prudence ^b   Rowland, Rosalind ^a   Sheehy, Susanne H ^a   Poulton, Ian D ^a   Hutchings, Claire ^a   Todryk, Stephen ^a   Andrews, Laura ^a   Folgori, Antonella ^a   Berrie, Eleanor ^b   Moyle, Sarah ^b   Nicosia, Alfredo ^c,d   Colloca, Stefano ^c   Cortese, Riccardo ^c,d   Siani, Loredana ^c   Lawrie, Alison M ^a   Gilbert, Sarah C ^a   Hill, Adrian V S ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CEINGE ^*  (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHIMPANZEE ADENOVIRUS 63 VECTOR; GAMMA INTERFERON; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; MULTIPLE EPITOPE THROMBOSPONDIN RELATED ADHESION PROTEIN VACCINE; PARASITE ANTIGEN; THROMBOSPONDIN RELATED ADHESION PROTEIN ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMMON COLD; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; FATIGUE; FEVER; FLOW CYTOMETRY; HEADACHE; HEAT; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTOPOIESIS; MALAISE; MALARIA FALCIPARUM; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DISEASE; SWELLING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOVIRUSES, SIMIAN; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MALARIA VACCINES; MALARIA, FALCIPARUM; PROTOZOAN PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA;

EID: 84856880087     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir850     Document Type: Article

References (26)

1. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest 2010; 120:4168-78.
2. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967; 216:160-2.
3. Khusmith S, Sedegah M, Hoffman SL. Complete protection against Plasmodium yoelii by adoptive transfer of a CD81 cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun 1994; 62:2979-83. (Pubitemid 24203986)
4. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989; 341:323-6. (Pubitemid 20102099)
5. Reyes-Sandoval A, Wyllie DH, Bauza K, et al. CD81 T effector memory cells protect against liver-stage malaria. J Immunol 2011; 187:1347-57.
6. Schmidt NW, Butler NS, Badovinac VP, Harty JT. Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 2010; 6:e1000998.
7. Hill AV, Reyes-Sandoval A, O'Hara G, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6:78-83.
8. PlebanskiM, Gilbert SC, Schneider J, et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998; 28:4345-55. (Pubitemid 28558665)
9. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011; 23:377-82.
10. Webster DP, Dunachie S, McConkey S, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006; 24:3026-34.
11. Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005; 191:619-26. (Pubitemid 40216679)
12. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
13. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10:616-29. (Pubitemid 39272851)
14. Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009; 27:3501-4.
15. Reyes-Sandoval A, Sridhar S, Berthoud T, et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008; 38:732-41.
16. Capone S, Reyes-Sandoval A, Naddeo M, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunization in non-human primates. Vaccine 2010; 29:256-65.
17. Bejon P, Ogada E, Mwangi T, et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One 2007; 2:e707.
18. Dunachie SJ, Walther M, Epstein JE, et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74:5933-42. (Pubitemid 44484581)
19. Keating SM, Bejon P, Berthoud T, et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005; 175:5675-80. (Pubitemid 41508049)
20. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13.
21. Peiperl L, Morgan C, Moodie Z, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One 2010; 5:e13579.
22. Webster D, Dunachie S, McConkey S, et al. Safety of recombinant fowlpox strain 9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria non-immune volunteers. Vaccine 2005; 3026-34.
23. Moorthy VS, Imoukhuede EB, Milligan P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004; 1:e33.
24. Bejon P, Mwacharo J, KaiO, et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 2006; 1:e29.
25. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005; 102:4836-41. (Pubitemid 40471540)
26. Asmuth DM, Brown EL, DiNubile MJ, et al. Comparative cellmediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010; 201:132-41.